Oncorus, Gaeta Therapeutics Ink Cancer Candidate Licensing Agreement

  • Oncorus Inc ONCR has signed an exclusive licensing agreement with Gaeta Therapeutics Ltd, related to the use of locally delivered Interleukin-12 (IL-12) via oncolytic viral expression in combination with an immune checkpoint inhibitor. 
  • IL-12 is one of five immunomodulatory payloads in Oncorus' lead viral immunotherapy product candidate, ONCR-177. 
  • Oncorus is enrolling patients in a Phase 1 trial to evaluate ONCR-177 alone and combined with Merck & Co Inc's MRK Keytruda (pembrolizumab) in patients with advanced or refractory cutaneous, subcutaneous or metastatic nodal or with liver metastases of solid tumors. 
  • Gaeta will receive an upfront payment of $0.2 million and is eligible to receive up to $7.5 million in milestone payments on a product-by-product and indication-by-indication basis.
  • Being developed for multiple solid tumor indications, ONCR-177 is an intratumorally administered oncolytic Herpes Simplex Virus (HSV)-based viral immunotherapy engineered to induce immunogenic cancer cell death. 
  • Price Action: ONCR shares traded lower by 0.18% at $10.80 on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareContractsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!